Drug development for Alzheimer's disease and dementia is a rapidly evolving field focused on combating cognitive decline and managing symptoms. Researchers target beta-amyloid plaques and tau tangles, pivotal in Alzheimer's pathology, alongside efforts to enhance neurotransmitter function and mitigate brain inflammation. Innovative therapies include monoclonal antibodies to clear amyloid plaques, small molecules targeting tau protein aggregation, and drugs modulating neurotransmitters like acetylcholine. Regenerative strategies such as stem cell therapies aim to repair brain tissue damage. This multifaceted approach aims not only to alleviate symptoms but also to slow or halt disease progression, offering promise for enhancing patients' quality of life in the future.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Cogs Club: Making a difference
Jacqueline Tuppen, Cogs Club, United Kingdom
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States